BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Oct 28, 2025; 31(40): 111727
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111727
Figure 1
Figure 1 Flowchart of cohort used. HCC: Hepatocellular carcinoma.
Figure 2
Figure 2 Trend of GALAD score across healthy individuals, patients with compensated cirrhosis and hepatocellular carcinoma. HCC: Hepatocellular carcinoma; CLD: Chronic liver disease.
Figure 3
Figure 3 Area under curve (receiver operating characteristic) of GALAD score. A: Optimal cut-off for healthy and hepatocellular carcinoma subjects; B: Optimal cut-off for cirrhosis and hepatocellular carcinoma subjects. ROC: Receiver operating characteristic; PPV: Positive predictive value; NPV: Negative predictive value.